A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Phase 1/2 Terminated
95 enrolled
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Phase 1/2 Terminated
5 enrolled 9 charts
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Terminated
87 enrolled 29 charts
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Phase 1/2 Terminated
4 enrolled 5 charts
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Phase 1/2 Terminated
2 enrolled 13 charts
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Phase 1/2 Terminated
17 enrolled 20 charts
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Phase 1/2 Terminated
89 enrolled 20 charts
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase 1/2 Terminated
65 enrolled 7 charts
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Phase 1/2 Terminated
8 enrolled 14 charts
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
Phase 1/2 Terminated
92 enrolled
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Phase 1/2 Terminated
79 enrolled 22 charts
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Phase 1/2 Terminated
5 enrolled 12 charts
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Phase 1/2 Terminated
15 enrolled 9 charts
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 29 charts
GEN206
Phase 1/2 Terminated
9 enrolled 8 charts
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
Phase 1/2 Terminated
15 enrolled
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Phase 1/2 Terminated
25 enrolled
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase 1/2 Terminated
2 enrolled 9 charts
RITCOLON
Phase 1/2 Terminated
7 enrolled
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Phase 1/2 Terminated
140 enrolled
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Phase 1/2 Terminated
3 enrolled 10 charts
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Phase 1/2 Terminated
33 enrolled 14 charts
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Phase 1/2 Terminated
5 enrolled 9 charts
Special Combination of BBI608 and Pembrolizumab
Phase 1/2 Terminated
55 enrolled
IMPACT-CRC
Phase 1/2 Terminated
85 enrolled
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
Phase 1/2 Terminated
32 enrolled 18 charts
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled 4 charts
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Phase 1/2 Terminated
6 enrolled 8 charts
PembroMab
Phase 1/2 Terminated
16 enrolled 6 charts
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
TCR-CRC-001
Phase 1/2 Terminated
1 enrolled
PARAGON
Phase 1/2 Terminated
4 enrolled 5 charts
NivoPlus
Phase 1/2 Terminated
33 enrolled
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
Phase 1/2 Terminated
6 enrolled
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Phase 1/2 Terminated
18 enrolled 23 charts
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Phase 1/2 Terminated
4 enrolled
IXO+A
Phase 1/2 Terminated
23 enrolled
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
Phase 1/2 Terminated
10 enrolled
The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases
Phase 1/2 Terminated
80 enrolled
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
Phase 1/2 Terminated
30 enrolled
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Phase 1/2 Terminated
14 enrolled
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Phase 1/2 Terminated
14 enrolled
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
Phase 1/2 Terminated
30 enrolled